欧盟委员会(EC)已批准口服JAK抑制剂Xeljanz(tofacitinib，5mg片剂，每日2次)，联合甲氨蝶呤(MTX)，用于对一种或多种疾病修饰抗风湿药物治疗反应不足或不耐受的中度至重度类风湿性关节炎(RA)成人患者的治疗;若患者对甲氨蝶呤不耐受或不适合甲氨蝶呤治疗，Xeljanz可作为单药疗法治疗。Tofacitinib是一种Janus激酶(JAK)抑制剂。JAKs是细胞内酶其传输信号发生来自细胞因子或生长因子-受体相互作用在细胞膜上影响造血和免疫细胞功能的细胞过程。在信号通路内，JAKs磷酸化和激活信号转导物和转录激活因子(STATs)调节细胞内的活性包括基因表达。Tofacitinib在JAKs点调控信号通路，预防STATs磷酸化和激活。JAK酶通过JAKs配对传输细胞因子信号(如，JAK1/JAK3，JAK1/JAK2，JAK1/TyK2，JAK2/JAK2)。Tofacitinib在体外抑制JAK1/JAK2，JAK1/JAK3，和JAK2/JAK2的活性联合有IC50分别为406，56,和1377 nM。但是，不知道特异性JAK组合与治疗有效性的关联。

The European commission (EC) has approved the oral JAK inhibitor Xeljanz(tofacitinib, 5mg tablet, twice daily) in combination with methotrexate (MTX) for the treatment of adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease-modified antirheumatic drugs; Xeljanz can be used as a monotherapy for patients who are intolerant or unsuitable for methotrexate therapy. Tofacitinib is an inhibitor of Janus kinase (JAK). JAKs are intracellular enzymes whose signaling comes from cytokine or growth factor-receptor interactions on the cell membrane that affect hematopoietic and immune cell function. Within signaling pathways, JAKs phosphorylates and activates signal transducers and transcriptional activators (STATs) that regulate intracellular activity including gene expression. Tofacitinib regulates signaling at the JAKs site, preventing phosphorylation and activation of STATs. JAK enzymes transmit cytokine signals through JAKs pairing (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 in vitro with IC50 values of 406,56, and 1377 nM, respectively. However, the association between specific JAK combinations and treatment effectiveness is unknown.

1.印度代购提示您，本品中国价格

原研药：暂无资料

仿制药：暂无资料

中国医保价格：暂无价格

2.印度代购提示您，本品印度价格

原研药：（5mg/60片/盒）23200卢比

仿制药：暂无资料

3.印度代购提示您，本品美国价格

原研药：（5mg/30片/盒）3579.98美元

仿制药：暂无资料

4.印度代购提示您，本品欧盟价格

原研药：（5mg/56片/盒）3313.48欧元

仿制药：暂无资料

5.印度代购提示您，本品日本价格

原研药：（5mg/30片/盒）2859.6日元/片

仿制药：暂无资料